Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Vector Vaccine Against Influenza A in Healthy Volunteers in 3 Groups With a Dose Escalation

NCT03651544 is registered in ClinicalTrials.gov with Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation as lead sponsor.

NCT NCT03651544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03651544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Vector Vaccine Against Influenza A in Healthy Volunteers in 3 Groups With a Dose Escalation
Lead sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Phase
Phase 1
Overall status
Completed
Start date
October 15, 2018
Completion date
March 14, 2019
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza a, influenza a virus infection, influenza epidemic, influenza h5n1